Joint symposium with the ISHLT: End-stage PAH - how and what do we do in 2021?

28 October 2021

A PVRI 2024 Digital webinar

Presentations 

  • When should a PH patient be considered for lung transplant? John Granton 
  • Atrial septum defect creation or mechanical support for end-stage PAH Erika Rosenzweig 
  • Lung and Heart-lung Transplant in 2021 – how well do PAH patients do? Eugene Golts
  • Pluripotent stem cell-based approaches and the future of artificial lungs Ulrich Martin
  • Timing and extent of ventricular reverse remodelling after lung transplant for PH Ryan Tedford 

Polls

Start of webinar poll (18 responses)

1. Talk 1: Improving survival AND quality of life are equally important considerations when considering timing of transplantation for PAH.

Agree - 100%

Disagree - 0%

 

2. Talk 2: Atrial septostomy can be used as a palliative bridge for end-stage PAH?

Agree - 66.67%

Disagree - 33.33%

 

3. Talk 3: the timing of referral for the Lung Transplantation for Pulmonary Hypertension should be solely determined based on available risk calculators?

Yes - 27.78%

No - 72.22%

 

4. Talk 4: Treatment of pulmonary arterial hypertension via iPS-based cellular therapies will become reality during the next 15 years

Yes - 72.22% 

No - 27.78%

 

5. Talk 5: Patients with end-stage PAH and very severe RV dysfunction should be considered for heart-lung transplant rather than isolated (bilateral) lung

Yes - 66.67%

No - 33.33%

 

End of webinar poll (6 responses)

1. Talk 1: Improving survival AND quality of life are equally important considerations when considering timing of transplantation for PAH.

Agree - 100%

Disagree - 0%

 

2. Talk 2: Atrial septostomy can be used as a palliative bridge for end-stage PAH?

Agree - 100%

Disagree - 0%

 

3. Talk 3: the timing of referral for the Lung Transplantation for Pulmonary Hypertension should be solely determined based on available risk calculators?

Yes - 33.33% 

No - 66.67%

 

4. Talk 4: Treatment of pulmonary arterial hypertension via iPS-based cellular therapies will become reality during the next 15 years

Yes - 33.33% 

No - 66.67%

 

5. Talk 5: Patients with end-stage PAH and very severe RV dysfunction should be considered for heart-lung transplant rather than isolated (bilateral) lung

Yes - 50%

No - 50%

Speakers and moderators

Paul Corris, Newcastle University, UK
John Granton, University of Toronto, Canada
Erika Rosenzweig, Columbia University Medical Center, USA
Eugene Golts, University of California San Diego, USA
Ulrich Martin, Hannover Medical School, Germany
Ryan Tedford, Medical University of South Carolina, USA
Share:

Other materials on this topic

13 November 2024

Reply to the letter to the editor entitled “Bridging the species divide: The limits of rat models in capturing human PVOD mechanisms” by Perros F. et al.

Dear Editor,
We thank Drs. Perros, Chaveroux, and Montani for their interest in our articles describing the activation of the integrated stress response (ISR) pathway as a mechanism underlying the pathogenesis of pulmonary veno-occlusive disease (PVOD), based on the rat mitomycin C (MMC) model of PVOD.

Pulmonary Circulation
18 October 2024

Congruency between clinician-assessed risk and calculated risk of 1-year mortality in patients with pulmonary arterial hypertension: A retrospective chart review

The objective of this analysis was to compare clinician-based and formally calculated risk assessments by REVEAL Lite 2 and COMPERA 2.0 and to characterize parenteral prostacyclin utilization within 90 days of baseline in high-risk patients. A multisite, double-blind, retrospective chart review of patients with pulmonary arterial hypertension (PAH) was conducted with an index period of January 2014–March 2017.

Pulmonary Circulation
Additional comments are available to members. Login or register to become a member today
RegisterorLogin to view